![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Pfirrmann, Markus; Evtimova, D.; Saussele, S.; Castagnetti, F.; Cervantes, F.; Janssen, Jan; Hoffmann, Verena; Gugliotta, G.; Hehlmann, R.; Hochhaus, A.; Hasford, Joerg und Baccarani, M.
(12. Januar 2017):
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
In: Journal of Cancer Research and Clinical Oncology, Bd. 143, Nr. 5: S. 843-850
Pfirrmann, Markus; Baccarani, M.; Saußele, Susanne; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V. S.; Castagnetti, F.; Hasford, Joerg; Hehlmann, R. und Simonsson, B.
(2016):
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 1: S. 48-56
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Castagnetti, F.; Raimondo, F. di; Simonsson, B.; Indrak, K.; Sninska, Z.; Sacha, T.; Clark, R.; Bogdanovic, A.; Hellmann, A.; Griskevicius, L.; Schubert-Fritschle, Gabriele; Sertic, D.; Guilhot, J.; Lejniece, S.; Zupan, I.; Burgstaller, S.; Koskenvesa, P.; Everaus, H.; Costeas, P.; Lindörfer, Doris; Rosti, G.; Saussele, S.; Hochhaus, A.; Hehlmann, R.; Turkina, A. und Casado, L. F.
(2016):
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
In: Leukemia, Bd. 31, Nr. 3: S. 593-601
Voskanyan, A.; Dietz, C. T.; Fabarius, A. C.; Lauseker, M.; Saußele, S.; Kalmanti, L.; Rinaldetti, S.; Haferlach, C.; Pfirrmann, M.; Hasford, J.; Baerlocher, G. M.; Hochhaus, A.; Baccarani, M. und Hehlmann, R.
(2016):
Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV.
In: Oncology Research and Treatment, Bd. 39: S. 52-53
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Lindörfer, Doris; Burgstaller, S.; Sertic, D.; Costeas, P.; Mayer, J.; Indrak, K.; Everaus, H.; Koskenvesa, P.; Guilhot, J.; Schubert-Fritschle, Gabriele; Castagnetti, F.; Di Raimondo, F.; Lejniece, S.; Griskevicius, L.; Thielen, N.; Sacha, T.; Hellmann, A.; Turkina, A. G.; Zaritskey, A.; Bogdanovic, A.; Sninska, Z.; Zupan, I.; Steegmann, J. L.; Simonsson, B.; Clark, R. E.; Covelli, A.; Guidi, G. und Hehlmann, R.
(2015):
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
In: Leukemia, Bd. 29, Nr. 6: S. 1336-1343
Hoffmann, V. S.; Baccarani, M.; Lindörfer, Doris; Castagnetti, F.; Turkina, A.; Zaritsky, A.; Hellmann, A.; Prejzner, W.; Steegmann, J. L.; Mayer, J.; Indrak, K.; Colita, A.; Rosti, G. und Pfirrmann, Markus
(2013):
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
In: Leukemia, Bd. 27, Nr. 10: S. 2016-2022
Hoffmann, Verena; Baccarani, M.; Hasford, Joerg; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2012):
The EUTOS CML score aims to support clinical decision-making.
In: Blood, Bd. 119, Nr. 12: S. 2966-2967
Hehlmann, R.; Grimwade, D.; Simonsson, B.; Apperley, J.; Baccarani, M.; Barbui, T.; Barosi, G.; Bassan, R.; Béné, M. C.; Berger, Ursula; Büchner, T.; Burnett, A.; Cross, N. C.; de Witte, T. J.; Dohner, H.; Dombret, H.; Einsele, H.; Engelich, G.; Foa, R.; Fonatsch, C.; Gökbuget, Nicola; Gluckman, E.; Gratwohl, A.; Guilhot, F.; Haferlach, C.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hochhaus, A.; Hoelzer, D.; Kiladjian, J. J.; Labar, B.; Ljungman, P.; Mansmann, Ulrich; Niederwieser, D. W.; Ossenkoppele, G.; Ribera, J. M.; Rieder, H.; Serve, H.; Schrotz-King, P.; Sanz, M. A. und Saußele, Susanne
(2011):
The European LeukemiaNet: achievements and perspectives.
In: Haematologica, Bd. 96, Nr. 1: S. 156-162
Hasford, Joerg; Baccarani, M.; Hoffmann, Verena; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2011):
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
In: Blood, Bd. 118, Nr. 3: S. 686-692
Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Baccarani, M.; Guilhot, F.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Thaler, J. und Steegmann, J. L.
(2003):
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
In: Seminars in Hematology, Bd. 40, Nr. 1: S. 4-12
Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Allan, N. C.; Baccarani, M.; Kluin-Nelemans, J. C.; Alimena, G.; Steegmann, J. L. und Ansari, H.
(3. Juni 1998):
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
In: Journal of the National Cancer Institute, Bd. 90, Nr. 11: S. 850-859